PRA Health Sciences Stock Price, News & Analysis (NASDAQ:PRAH)

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) announced its quarterly earnings data on Wednesday, July, 31st. The medical research company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.11 by $0.11. The medical research company had revenue of $763.31 million for the quarter, compared to analyst estimates of $764.95 million. PRA Health Sciences had a net margin of 5.39% and a return on equity of 26.64%. The company's revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.00 earnings per share. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences will be holding an earnings conference call on Wednesday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

PRA Health Sciences issued an update on its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided earnings per share (EPS) guidance of $4.98-5.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.01. The company issued revenue guidance of $3.02-3.1 billion, compared to the consensus revenue estimate of $3.1 billion.

9 equities research analysts have issued 12 month price targets for PRA Health Sciences' shares. Their predictions range from $100.00 to $126.00. On average, they expect PRA Health Sciences' stock price to reach $115.86 in the next twelve months. This suggests a possible upside of 19.7% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PRA Health Sciences.

Headlines about PRAH stock have been trending somewhat positive this week, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. PRA Health Sciences earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for PRA Health Sciences.

Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and Pieris Pharmaceuticals (PIRS).

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Adobe (ADBE), Applied Materials (AMAT), Paypal (PYPL), Lam Research (LRCX), Veeva Systems (VEEV), Netflix (NFLX), Splunk (SPLK) and GrubHub (GRUB).

(PRAH) raised $306 million in an IPO on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Artemis Investment Management LLP (0.36%), CIBC Private Wealth Group LLC (0.26%), Scout Investments Inc. (0.14%), Reilly Financial Advisors LLC (0.13%), Pacer Advisors Inc. (0.03%) and State of Alaska Department of Revenue (0.02%). Company insiders that own PRA Health Sciences stock include David W Dockhorn, Fund Holdings LP Kkr, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC, Scout Investments Inc., Campbell & CO Investment Adviser LLC, Pacer Advisors Inc. and CIBC Private Wealth Group LLC. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was acquired by a variety of institutional investors in the last quarter, including Reilly Financial Advisors LLC, Artemis Investment Management LLP, Fox Run Management L.L.C., State of Alaska Department of Revenue and Toth Financial Advisory Corp. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $96.79.

PRA Health Sciences has a market capitalization of $6.38 billion and generates $2.87 billion in revenue each year. The medical research company earns $153.90 million in net income (profit) each year or $3.93 on an earnings per share basis. PRA Health Sciences employs 16,400 workers across the globe.View Additional Information About PRA Health Sciences.

The official website for PRA Health Sciences is http://www.prahs.com/.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]